摘要
目的探讨胆管癌特异性神经、淋巴道转移与其基质金属蛋白酶MMP-9的表达及其意义。
方法将C57BL/6小鼠淋巴结、神经组织匀浆及无血清培养基与胆管癌细胞株(Q-BC939)共孵育,采用双抗体夹心式酶联免疫吸附法(ELISA)检测其分泌上清MMP-9表达水平。
结果在无血清培养液培养条件下胆管癌细胞QBC939分泌较少MMP-9(19.93±2.94),QBC939与C57BL/6小鼠淋巴结、神经组织匀浆孵育后分泌MMP-9量,分别为淋巴(27.33±3.98)、神经(27.16±4.12)。淋巴、神经匀浆组高于无血清培养液组MMP-9分泌量(P＜0.001)。
结论QBC939在淋巴结、神经成分诱导下能分泌较多的MMP-9,这可能与它们具有特异性地向淋巴结、神经转移的功能密切相关。
Objective To study the Significance of matrix metalloproteinases activity in cholangiocarcinoma cell with different lymphatic and nerval metastasis potential.
Methods Sandwich enzyme-linked immunosorbent assay(ELISA) was used to detect the difference of MMP-9 product and activities in cholangiocarcinoma cell line(QBC939) that were incubated in serum-free medium,homogenate of lymph node or nerve tissue,respectively.
Results After incubation in the serum-free medium,the production of MMP-9 was at the low level in QBC939(19.93±2.94).AfterQBC939 were incubated in homogenate of lymph node,nerve the expression of MMP-9 was upregulated apparently,which were(27.33±3.98),(27.16±4.11) respectively,higher than that of the serum-free medium(P＜0.001).
Conclusion:Hostmicroenvironment could contribute to the increasing of MMP-9 in QBC939,which is closely correlated to their specific lymphatic nerval metastasis potential.
引文
1.Bertin N,Clezardin P,Kubiak R,Frappart L.Thrombospondin-1 and -2 messenger RNA expression in normal,benign,and neoplastic human breast tissues:correlation with prognostic factors,angiogenesis,and fibroblastic desmoplasia.Cancer Res.1997;57:396-9.
2.Terada T,Okada Y,Nakanuma Y.Expression of immunoreactive matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in human normal livers and primary liver tumors.Hepatology 1996;23:1341-4.
3.Kunio Ok-uda,Yasuni Nakanuma,Masaru Miyazaki.Cholangiocarcinoma:Recent progress.Part 2:Molecular pathology and treatment.J Gastroenterology and Hepatology 2002,17:10-1056
4.Stephanie C,Graeme IM.Matrix metalloproteinases in tumour invasionand metast- asis.J Pathol,1999,189,300-308.
5.Massova I,Kotra LR,Fridman R.Matrix metalloproteinases:structure,evolution,a- nd diversification FASEB J 1998,273:10671-10681.
6.侯力 凌茂英 吕申 辛毅 李莹 王怀莲 小鼠肝癌细胞特异性淋巴道转移与其基质金属蛋白酶分泌的关系.中华病理学杂志,2000;29(4):276-278.
7.冀学宁 叶胜龙 李雁 田波 陈洁 刘银坤 汤钊猷 人肝癌细胞器官特异性转移与基质金属蛋白酶分泌的关系.中华实验外科杂志,2003;20(9):799-801.
1.Furubo S,Harada K,Shimonishi T,Katayanagi K,Tsui W,Nakanuma Y.Protein expression and genetic alterations of p53 and ras in intrahepatic cholangiocarcinoma Histopathologty 1995;35:230-40.
2.Jaiswal M.LaRusso N F,Burgart LJ.Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide,dependent mechanism.Cancer Res.2000;60:184-90.
3.Ohashi K。Nakajima Y,Kanehiro H et al.Ki-ras mutations and p53 protein expressions in intrahepatic cholangiocarcinomas:relation to gross tumor morphology.Gastroenteroloqy 1995;136:1612-17.
4.Harnois DM,Que FG,Celli A,LaRusso NF,Cores GJ.Bcl一2 is overexpressed and alters the threshold for apoptosis in a cholangiocarcinoma celI|ine.Hepatology 1997;26:884-90.
5.Albores.Saved CJ,Scoazec J.Wittekind C et al.Carcinoma of the gallbladder and extrahepatic bile ducts.In:Hamilton SR.Aaltonen LAeds.WHO Classification of Tumors,Pathology and Genetics,Tumors of the Digestive System Geneva:IARC Press.2000;206-17.
6.Majano PL,Garcia—Monzon C,Lopez—Cabrera M et al.Inducible nitric oxide synthase expression in chronic viral hepatitis:evidence for a virus.induced gene-up-reguation.J.Clin.Invest.1998;101:1343-52
7.Yasoshima M,Kono N,Sugawara H,Katayanagi K,NakanumaY.Increased expression of interleukin-6 and tumor necrosis factor-alpha in pathologic biliary epithelial cells:in situ and culture study.Lab.Invest.1998;78:89-100.
8.Mannick JB,Hansladen A,Liu L et al.Fas-induced caspase denitrosylatiOn.Science 1999;284:651-4.
9.Ballatori N,Jacob R,Barrett C,Boyer JL.Biliary catabolism of glutathione and differential reabsorption of its amino acid constituents.Am.J.Physiol.1988;254:G1-7.
10.Celli A,Que FG.Dysrequlation of apoptosis in the cholanqiopathies and cholangiocarcinoma.Semin.Liver Dis.1998:18:177-85.
11.Terada T,Ashida K,Endo K et al,c-erbB-2 protein is expressed in hepatolithiasis and cholangiocarcinoma.Histopathology 1998;33:325-31.cholangiocarcinoma.Histopathology 1998;33:145-53.
20.Lai GH,Radaeva S,Nakamura T,Sirica AE.Unique epithelial cell production of hepatocyte growth factorlscatter factor by putative precancerous intestinal metaplasias and associated intestinal—type biliary cancer chemically induced in rat liver. Hepatology 2000; 31: 1 257-65.
21. Hamois DM, Que FG, CelI A, LaRusso N F, Gores GJ. Bcl-2 is Overexpressed and alters the threshold for apoptosis in a cholangiocarcinoma celI line. Hepatology 1997; 26: 884—90.
22. lwata M,Harada K, Kono N, Kaneko S, Kobayashi K, Nakanuma Y.Expression of Bcl — 2 familial proteins is reduced in sinail bile duct lesions of primarv biliary cirrhosis. Hum. Pathol. 2000; 31: 179—84.
23. Charlotte F,L'Hermine A. Martin N et al. Immunohistochemical detection of bcl-2 protein in normal and pathological human liver. Am. J. Pathol. 1994; 144: 460-5.
24. lto Y,rakeda T,Sakaki Y et al. Bcl-2 expression in cholanaiocellular carcinoma is inversely correlated with biologically aggressive phenotypes. Oncology 2000; 59: 63-7.
25. Arora DS,Ramsdale J, Lodge JP,Wyatt Jl. p53 but not bcl-2 is expressed by most cholangiocarcinomas. A study of 28 cases. Histopathology 1 999; 34: 497-501.
26. Goggins M, Shekher M, Turnacioglu K, Yeo CJ, Hruban RH, Kern SE. Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas. Cancer Res. 1998; 58: 5329-32.
27. Nagai M, Kawarada Y. Watanabe M et al. Analysis of microsatellite instability. TGF. beta type II receptor gene mutations and hMSH2 and hMLH1 allele losses in pancreaticobiliary maljunction. associated' biliary tract tumors. Anticancer Res. 1999; 19: 1765—8.
28. Miyazaki M, Ohashi R, Tsuji T,Mihara K, Gohda E, Namba M. Transforming growth factor—betal stimulates or inhibits cell growth via down-or up—regulation of p21/Waf1. Biochem. Biophys. Res. Commun. 1998; 246: 873—80.
29. Ozaki S, Harada K, Sanzen TIWatanabe KWS, Tsui Nakanuma Y.In situnucleic acid detection of human telomerase in intrahepatic cholangiocarcinoma and its preneoplastic lesion. Hepatology 1999; 30: 914—19.
30. Watanabe M, Asaka M, Tanaka J, Kurosawa M, Kasai M, Miyazaki T.Point mutation of K. ras gene codon 12 in biliary tracttumors. Gastroenterology 1994: 107: 1147-53.
31. Petmitr S, Pinlaor S, Thousunanoen A, Karalak A,Migasena P.K-ras oncogene and p53 gene mutations in cholangiocarcinoma from Thai patients. Southeast Asian J. Trop. Med. Public Health 1998; 29: 71-5.
32. Ohashi K,TSutsumi M,Nakajima Y et al. High rates of Ki-ras point mutation in both intra-and extra. hepatic cholangiocaricnomas. Jpn. J. Clin. Oncol. 1994; 24: 305-10.
33. Tsuda H , Satarug S , Bhudhisawasdi V,Kihana T , Sugimura T , Hirohashi s. Cholangiocarcinomas in Japanese and Thai patients: difference in etiologh and incidence of point mutation of the C. Ki-ras proto—oncogene. Mol. Carcinog. 1992; 6: 266-9.
34. Kang YK, Kim WH, Lee HK, Kim Yl. Mutation of p53 and K-ras, and loss of heterozygosity of APC in intrahepatic cholangiocarcinoma. Lab. Invest. 1999; 79: 477—83.
35. HigashiM. Yonezawa S,HoJJ et al. Expression of MUC1 and MUC2 mucin antigens in intrahepatic bile duct tumors: its relationship with a new morphological classification of cholangiocarcinoma. Hepatology 1999; 30: 1347-55.
36. Yonezawa S, Sueyoshi K, Nomoto M et al. MUC2 gene expression is found in noninvasive tumors but not in invasive tumors of the pancreas and liver. its close relationship with prognosis of the patients, hum., Pathol. 1997; 28: 344-52.
37. Shimonishl T,Miyazaki K, Nakanuma Y. Cytokeratin profile relates to histological subtypes and intrahepatic location of intrahepatic cholangiocarcinoma and primary sites of metastatic adenocarcinoma of liver. Histopathology 2000; 37: 55-63.
38. Rullier A, Le Bail B, Fawaz R, Blanc J, Bioulac. Sage P. Cytokeratin7 and 20 expression in cholangiocarcinomas varies along the biliary Surg. Pathol 2000; 24: 870—6.
39. Terada T,Makimoto K, Terayama N, Suzuki Y, Nakanuma Y. Alpha—smooth muscle actin. positive stromal cells in cholangiocarcinomas, hepatocellular carcinomas and metastatic liver carcinomas. J. Hepatol. 1996; 24: 706-12.
40. Roskams T, De Vos R, David G, Van Damme B, Desmet V. Heparan. sulphate proteoglycan expression in human primary liver tumours. J. Pathol. 1998: 185: 290-7.
41 . Akahane T, Ishii M, Ohtani H, Nagura H, Toyota TStromal exprelssion of urokinase. type plasminogen activator receptor(uPAR)is associated with invasive growth in primary liver cancer. Liver 1998: 18: 414-19.
42. Kawahara N, Ono M, Taguchi K et al.Enhanced expression of thrombospondin-1 and hypvascularity in human cholangiocarcinoma. Hepatology 1998; 28: 1512-17.
43. Bertin N,Clezardin P,Kubiak R, Frappart L. Thrombospondin-1 and-2 messenger RNA expression in normal, benign, and neoplastic human breast tissues: correlation with prognostic factors . tumor angiogenesis , and fibroblastic desmoplasia. Cancer Res. 1997; 57: 396—9.
44. Facchetti F,Vermi W,FiorentiniS et al. Expression of jducible nitric oxide synthase in human glanulomas and histiocytic reactions. Am. J. Pathol. 1999; 154: 145—52.
45. Terada T,Okada Y,Nakanuma Y.Expression of immunoreactive matrix metlloproteinases and tissue inhibitors of matrix metalloproteinases in human normal livers and primary liver tumors. Hepatology 1996; 23: 1341-4.
46. Ashida K, Terada T,Kitamura Y,Kaibara N. Expression of E-cadherin, alpha. catenin, beta. catenin, and CD44(standard and variant isoforms)in human cholangiocarcinoma: an immunohistochemical study. Hepatology 1998; 27.: 974-82
47. Kim HR, Lin HM,Biliran H, Raz A. Cell cycle arrest and inhibition of anoikis by galectin-3 in human breast epithelial cells. Cancer Res. 1999; 59: 4148—54.
48. Sasaki M, Morita T, Hoso M, Nakanuma Y,Tanimura H. Carcinoembryonic antigen and blood group. related carbohydrate antigens in glycoproteins in human bile in hepatolithiasis. Japanese Study Group of Hepatolithiasis. Hepatology 1996; 23: 258—63.
49. Regimbald LH, Pilarskl LM, Longenecker BM, Reddish MA, Zimmermann G, Hugh JC. The breast mucin MUC1 as a novel adhesion ligand for endothelial intercellular adhesion molecule 1 in breast cancer. Cancer Res. 1996; 56: 4244-9.
50. Hudson MJ, StampGW, Hollingsworth MA, Pignatelli M, lalni EN. MUC1 expressed in panC1 cells decreases adhesion to typel collagen but increases contraction in collagenlattices. Am. J. Pathol. 1996: 148: 951-60.
51. Ho JJL, Cheng S,KimYS. Access to peptide regions of a su rface mucin(MUC1)is reduced by sialic acids. Biochem. Biophys. Res. Commun. 1995; 210: 866-73.
52. Nishioka NS .Dru9,light,and oxygen: a dynamic combination in the clinic. Gastroenterology 1998; 114: 604-6.
53. Song L-MWK, Wang KK,Zinsmeister AR. Mon0-1-asparty chlorine e6(Npe6)and hematoporphyrin derivative(HpD)in photodynamic therapy administered to a human cholangiocarcinoma model. Cancer 1998; 82: 421-7.
54. Ortner M-AEJ, Libertruth J, Schreiber S et al. Photodynamic therapy of nonresectable cholangiocarcinoma. Gastroenterology 1998; 82: 421-7.
55. Lieser MJ, Barry MK, Rouhand C, Ilstrup DM, Nagorney DM. Surgical management of intrahepatic cholangiocarcinoma: a 31 year experience. J. Hepatobiliary Pancreat. Surg. 1998; 5: 41-7.
56. Kawarada Y, Mizumoto R. Diagnosis, and treatment of cholangiocarcinoma of the liver. Hepatogastroenterology 1990; 37: 176-81.
57. Yamamoto J,Kosuge T,Takayama T et al . Surgical treatment of intrahepatic cholangiocarcinoma: four patients surviving more than five years. Surgery 1992; 111: 617-22.
58. Yamamoto J,Kosuge T,Takayama T et al . Surgical treatment of intrahepatic cholangiocarcinoma: four patients surviving more than five years. Surgery 1992; 111: 617-22.
59. MiyazakiM, ltoH, Nakagawa K et al. Aggressive surgical approaches to hilar cholangiocarcinoma: hepatic or local resection?Surgery 1998: 123: 131—6.
60. Nagino M, Kamiya J, Kanai M et al. Right treatment portal vein embolization for biliary tract carcinoma: technique and clinical utility. Surgery 2000; 127: 155. 60.
61. Ohashi K, Nakajima Y,Kanehin H et al. Ki-ras mutations and p53 protein expressions in intrahepatic cholangiocarcinoma: relation to gross tumor morphology. qastroenterology 1995; 109: 1612-17.
62. Tannapfel A,Weinams L,GeiBier F et al. Mutations of p53 tumor suppresser gene, apoptosis, and proliferation in intrahepatic cholangiocellular carcinoma of the liver. Dig. Dis. Sci.2000; 45: 317-24.
63. Cherqui D,Tantaw B,AIon Ret al. Intrahepatic cholangiocarcirloma. Arch. Surg. 1995; 130: 1073-8.
64. Berda SV,Delpero JR, Gorcia S, Hardwigsen J, Treut Y P, Awestern surgical experience of peripheral cholangiocarcinoma. Br. J. Surg. 1996; 83: 1517—21.
65. Casavilla FA, Marsh JW,lwatsuki S et al. Hepatic resection and transplantation for peripheral cholangiocarcinoma. J. Am. Coil. Sur9. 1997: 185: 429-36.
66. Pichlmeyer R, Wejmann A, Ringe B. Indication for liver transplantation in a hepatobiliary malignancy. Hepatology 1994; 20: 33S — 40S.
67. Jeyarazah DR, Klintmalm GB. is liver transplantation indicated for cholangiocarcinoma?J. Hepatobiliary Pancreat. Surg. 1998; 5: 48—51.
68. Alessiani M, Tzakis A, Todo S, Demetrius A J, Fung J J, Starzl TE. Assessment of five. year experience with abdominal organ cluster iranspIantation. J. Am.Coil. Surg. 1995: 180: 1-9.
69. Bismuth H, Chiche L, Adam R, Castaing D, Diamod T,Dennisi A. Liver resection versus transplantation for hepatocellUlar carcinoma in cirrhotic patients. Ann. Surg. 1993; 218: 145—51.
70 . Cherqui D , Alon R , Piedbois P et al . Combined liver transplantation and pancreatoduodenectomy for iirresectable hilar bile duct carcinoma. Br. J. Surg. 1995; 82: 397-8.
71. Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N. Engl. J. Med. 1996; 334: 693—9.